enGene Holdings Inc. (NASDAQ:ENGNW) Sees Significant Drop in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totaling 399 shares, a decline of 90.9% from the April 15th total of 4,399 shares. Based on an average daily volume of 8,555 shares, the days-to-cover ratio is currently 0.0 days.

enGene Stock Performance

NASDAQ:ENGNW traded down $0.01 during trading hours on Tuesday, reaching $0.16. The stock had a trading volume of 8,622 shares, compared to its average volume of 17,895. The stock has a 50 day simple moving average of $2.29 and a 200 day simple moving average of $2.61. enGene has a 12-month low of $0.11 and a 12-month high of $4.20.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.